dc 4

DC4 can be used to synthesize antibody-drug conjugate (ADC), which is an ADC cytotoxin. DC4 can be used for targeted therapy of tumors.

DC4 crosslinker, an 18Å mass spectrometry-cleavable crosslinking reagent, features two intrinsic positive charges facilitating the fragmentation of cross-linked peptides into their constituent peptides through collision-induced dissociation or in-source decay. Initial fragmentation leads to cleavage adjacent to the positive charges, enabling the identification of cross-linked peptides as pairs of ions with precise mass separation. Furthermore, the resultant intact peptide fragments can undergo further fragmentation, producing a sequence of b- and y-ions for peptide identification.

The IC50s of DC4SMe on Ramos, Namalwa and HL60 / s cancer cells were 1.9 nM, 2.9 nM and 1.8 nM, respectively. DC4SMe can be used for targeted therapy of tumors. DC4SMe is a phosphate prodrug of the cytotoxic DNA alkylating agent DC4 and can be used in the

5'-O-DMT-N4-Ac-2'-F-dC, a modified nucleoside, is utilized for synthesizing DNA or RNA.

5'-O-DMT-N4-Bz-2'-F-dC is a nucleoside with protective and modification effects.

5'-O-DMT-N4-Bz-5-Me-dC (DMT-NBZ-5-METHYL DC) is a modified nucleoside used in the synthesis of nucleoside phosphoramidites.

5'-O-DMT-N4-Ac-dC (N4-Acetyl-2'-deoxy-5'-O-DMT-cytidine, compound 7) is a deoxynucleoside used in synthesizing dodecyl phosphoramidite, a crucial precursor for dod-DNA production. Dod-DNA is amphiphilic DNA with dodecyl phosphotriester linkages, featuring an internal hydrophobic region[1][2].

4-CF3-TPP-DC is an inert mitochondriotropic carrier that does not induce mitochondrial depolarization or cell death in C2C12 cells.

A2-Iso5-4DC19, a lipidoid compound, effectively facilitates the delivery of agents, including polynucleotides, to cells [1].

A12-Iso5-4DC19 is an ionizable cationic lipid that enhances mRNA delivery and is utilized in research concerning RNA vaccines.

5'-O-DMTr-N4-Fmoc-5-Me-dC-phosphoramidite is a Nucleoside Phosphoramidite.

DC 432, a potent peptidomimetic inhibitor of N-terminal methyltransferase 1/2 (NTMT1/2) with an IC50 value of 54 nM, incorporates a BM30 peptide enhanced by five arginine residues. It effectively reduces the N-terminal methylation level of the regulator of chromosome condensation 1 and SET proteins in HCT116 cells, demonstrating cell permeability.

AZA197 (AZA-197) is a selective Cdc42 inhibitor. It acts by inhibiting primary colon cancer growth and prolonging survival in a preclinical mouse xenograft model by downregulation of PAK1 activity.

Bofutrelvir (FB2001) is a SARS-CoV-2 3CL protease inhibitor with antiviral activity for the study of novel coronavirus pneumonia (COVID-19) infections.

LDC4297 is a potent and selective CDK7 inhibitor with an IC50 of 0.13 nM.

ML241 is a potent and selective inhibitors of p97 ATPase.ML241 inhibits degradation of a p97-dependent but not a p97-independent proteasome substrate in a dual-reporter cell line. ML241 may be a novel agent for the chemotherapy of cancer, and provide a rationale for developing pathway-specific p97 inhibitors.

DC41SMe is a DC1 derivative that is cytotoxic to Ramos, Namalwa and HL60 / s with IC50s ranging from 18-25 pM. DC1 is a simplified analogue of CC-1065, an antibody conjugate of cytotoxic DNA alkylation molecules, used for targeted treatment of cancer.

DC41 is a derivative of DC1. DC1 is a simplified analogue of CC-1065, an antibody conjugate of cytotoxic DNA alkylating agents, used for targeted treatment of cancer.

The IC50 of DC44SMe for Ramos, Namalwa and HL60 / s cancer cells was 2.0 nM, 2.8 nM and 1.9 nM, respectively. DC44SMe can be used for targeted treatment of cancer. DC44SMe is a phosphate prodrug of DC44 and can be used in the synthesis of antibody-drug co

CUDC-427 (GDC-0917) is an orally bioactive and pan antagonist of inhibitor of apoptosis proteins(IAPs). CUDC-427 can be used in research on cancers.

MBQ-167 is a dual inhibitor of Rac/Cdc42 (IC50s: 103 nM for Rac 1/2/3 and 78 nM for Cdc42 in MDA-MB-231 cells, respectively).

NMS-873 is a potent and selective allosteric inhibitor of VCP/p97.

ZCL278 is a selective Cdc42 GTPase inhibitor.

DBEQ (JRF 12) is a selective, potent, reversible, and ATP-competitive p97 inhibitor.